



UNIVERSITÀ DEGLI STUDI DI MILANO  
FACOLTÀ DI FARMACIA

## ESTABLISHING CAUSALITY AND MANAGING UNCERTAINTY.

*“What evidence is needed to establish a causal relationship? How are uncertainty cause and quantitative uncertainty managed in assuring food safety?”*

Corrado Lodovico Galli

University of Milan - Italy

CRN-I Scientific Symposium

July 3, 2010

InterContinental Hotel Genève.

# CAUSALITY


“**Causality** is the relationship between an event (the cause) and a second event (the effect), where the second event is a consequence of the first.”



# STATISTICAL CAUSALITY

“**Causality** may be the relationship between an event (the storks) and a second event (the birth rate), where the second event is a consequence of the first.”






## Theory of the Storks (ThoS)

versus

## Theory of Sexual Reproduction (ThoSR)




# NEW EVIDENCE FOR THE THEORY OF THE STORK

Thomas Höfera, Hildegard Przyrembelb and Silvia Verleger

*Federal Institute for Risk Assessment, Berlin,*

*Office of the National Breast Feeding Committee at BfR, Berlin, and Independent Midwife, Berlin, Germany*



**Figure 1.** Storks and the birth rate in Lower Saxony, Germany (1971–2000). Open circles show yearly birthrates in hundreds in Lower Saxony. Full squares show numbers pairs of storks in Lower Saxony. Dotted lines represent linear regression trend ( $y = mx + b$ ).

*Paediatric and Perinatal Epidemiology 2004, 18, 88–92*




# NEW EVIDENCE FOR THE THEORY OF THE STORK

Thomas Höfera, Hildegard Przyrembelb and Silvia Verleger

*Federal Institute for Risk Assessment, Berlin,*

*Office of the National Breast Feeding Committee at BfR, Berlin, and Independent Midwife, Berlin, Germany*



*Paediatric and Perinatal Epidemiology 2004, 18, 88–92*




# NEW EVIDENCE FOR THE THEORY OF THE STORK

Thomas Höfera, Hildegard Przyrembelb and Silvia Verleger

*Federal Institute for Risk Assessment, Berlin,*

*Office of the National Breast Feeding Committee at BfR, Berlin, and Independent Midwife, Berlin, Germany*



*Paediatric and Perinatal Epidemiology 2004, 18, 88–92*



UNIVERSITÀ DEGLI STUDI DI MILANO  
FACOLTÀ DI FARMACIA


Laboratory of Toxicology

# CAUSALITY

“**Causality** is the relationship between an event (**storks**) and a second event (***out-of-hospital deliveries***), where the second event is a consequence of the first.”







## Theory of the Storks (ThoS)

Children are delivered by storks




# UNCERTAINTY

Uncertainty must be taken in a sense radically distinct from the familiar notion of risk

- **Risk:** A state of uncertainty where some possible outcomes have an undesired effect or significant loss.
  - **Measurement of Risk:** A set of measured uncertainties where some possible outcomes are losses, and the magnitudes of those losses – this also includes loss functions over continuous variables.
- **Uncertainty:** The lack of certainty, A state of having limited knowledge where it is impossible to exactly describe existing state or future outcome, more than one possible outcome.
  - **Measurement of Uncertainty:** A set of possible states or outcomes where probabilities are assigned to each possible state or outcome – this also includes the application of a probability density function to continuous variables



# PROPORTION OF CANCER DEATHS ATTRIBUTED TO VARIOUS ENVIRONMENTAL FACTORS




# BIOLOGICAL CAUSALITY

“**Causality** is the relationship between an event (the dose) and a second event (the response), where the second event is a consequence of the first.”




# DOSE - RESPONSE FOR CRITICAL EFFECTS


(to establish a dose without adverse effects in animals)




# EXPOSURE (dose – acute)



# EXPOSURE (dose and time – additive)




# EXPOSURE (dose and time – bioaccumulation)






# UNCERTAINTY FACTORS




# KEY EVENT I

## Methylene Chloride




# UNCERTAINTY FACTORS




# MECHANISTIC STUDIES

## *Dithiocarbamates (DTCs)*



# SPECIES DIFFERENCES

## *Dithiocarbamates*









# RISK CHARACTERIZATION

## ✓ Hazard identification

- ❖ Inherent biological activity,

## ✓ Hazard assessment

- ❖ Dose-response analysis
- ❖ Assessment of relevance for humans



# ANIMAL-BASED TOXICOLOGICAL STUDIES

## TOXICOKINETIC

Absorption  
Distribution  
Metabolism  
Excretion

## ACUTE TOXICITY

LD<sub>50</sub> oral  
LD<sub>50</sub> dermal  
LC<sub>50</sub> inhalation  
Skin irritation  
Eye irritation  
Skin sensitization

## GENOTOXICITY

Mutagenesis  
Clastogenesis  
Aneuploidy

## SHORT-TERM TOXICITY

Mouse	90 day toxicity
Rat	90 day toxicity
Dog	90 day toxicity
Dog	1 year toxicity

## DEVELOPMENTAL TOXICITY

Teratogenicity tests (Rat-Rabbit)

## REPRODUCTIVE TOXICITY

Two generation reproductive toxicity

## LONG-TERM TOXICITY and/or CARCINOGENICITY

Mouse 18 months  
Rat 104 weeks



# ANIMAL-BASED TOXICOLOGICAL STUDIES

## TOXICOKINETIC

Absorption  
Distribution  
Metabolism  
Excretion

## ACUTE TOXICITY

LD<sub>50</sub> oral  
LD<sub>50</sub> dermal  
LC<sub>50</sub> inhalation  
Skin irritation  
Eye irritation  
Skin sensitization

## GENOTOXICITY

Mutagenesis  
Clastogenesis  
Aneuploidy

# MODE OF ACTION

## SHORT-TERM TOXICITY

90 day toxicity  
90 day toxicity  
90 day toxicity  
1 year toxicity  
Rat  
Dog  
Dog

## DEVELOPMENTAL TOXICITY

Teratogenicity tests (Rat-Rabbit)

## REPRODUCTIVE TOXICITY

Two generation reproductive toxicity

## LONG-TERM TOXICITY and/or CARCINOGENICITY


Mouse 18 months  
Rat 104 weeks





# RISK CHARACTERIZATION

Hazard Assessment



Genotoxic Carcinogen




Toxicant and/or  
NON Genotoxic Carcinogen




# DOSE - RESPONSE FOR CRITICAL EFFECTS

(to establish a dose without adverse effects in animals)



# ANIMAL-BASED TOXICOLOGICAL STUDIES

(quantification of adverse health effects)



# ADMISSIBILE DAILY INTAKE

$$ADI = \frac{NOAEL}{SF}$$

ADI = Admissible Daily Intake mg/kg b.w.


NOAEL = No Observed Adverse Effect Level (mg/kg b.w.)

SF = Safety Factor (10, 100, n)



# RISK CHARACTERIZATION

Hazard Characterization




Genotoxic Carcinogen



Toxicant and/or  
NON Genotoxic Carcinogen




# DEOXYRIBONUCLEIC ACID (DNA)



<http://www.accessexcellence.org/AB/GG/chromosome.html>




# GENOTOXIC CARCINOGENS



# GENOTOXIC CARCINOGENS

Genetic mutation and cancer development



U.S. National Library of Medicine



UNIVERSITÀ DEGLI STUDI DI MILANO  
FACOLTÀ DI FARMACIA


Laboratory of Toxicology

32



# CARCINOGENS


DNA-reactive genotoxins



THRESHOLD ?



# RISK CHARACTERIZATION AND FORMULATION OF ADVICE TO RISK MANAGERS



# RISK CHARACTERIZATION AND FORMULATION OF ADVICE TO RISK MANAGERS

**Risk characterization for genotoxic carcinogens**



**ALARA**  
As low as  
reasonably  
achievable



**ALARP**  
As low as  
reasonably  
practicable



# ALARA

- ❖ Based solely on **hazard identification**
- ❖ Does not take into account **human exposure**
- ❖ Does not take into account **potency**



# LOW-DOSE EXTRAPOLATION


**Risk characterization for genotoxic carcinogens**



**Cancer risk  
Estimation**  
Based on  
low-dose  
extrapolation



# RISK ASSESSMENT



# RISK CHARACTERIZATION AND FORMULATION OF ADVICE TO RISK MANAGERS


**Risk characterization for genotoxic carcinogens**



**Margin of  
Exposure**  
(MOE)



# BENCHMARK DOSE





# MARGIN OF EXPOSURE (MOE)

$$\text{⌘ MOE} = \text{PoD} / \text{HUMAN EXPOSURE}$$

PoD = 25 mg/kg b.w.

EXPOSURE (Dietary Intake) = 0.00005 mg/kg/day

$$\text{⌘ MOE} = 25 / 0.00005 = \underline{58,000}$$



# RISK CHARACTERIZATION AND FORMULATION OF ADVICE TO RISK MANAGERS

**Risk characterization for genotoxic carcinogens**



**Threshold of  
toxicological  
Concern**  
(TTC)



# THRESHOLD OF TOXICOLOGICAL CONCERN (TTC) IN RISK CHARACTERISATION

## The threshold of toxicological concern (TTC)

is a pragmatic risk assessment tool that is  
based on the principle of:


*establishing a human exposure threshold value  
for all chemicals ( $1.5 \mu\text{g}/\text{person}/\text{day}$ )*

*below which there is a very low probability of an  
appreciable risk to human health.*



# COHORT OF CONCERN (CoC)

Compounds with a calculated risk  $>1$  in 1,000,000



# THRESHOLD OF TOXICOLOGICAL CONCERN (TTC) IN RISK CHARACTERISATION

## HOW TO APPLY THE TTC ?

- ❖ Stepwise approach on a case by case basis:
  - ❖ Cohort of Concern (CoC)? → **NO TTC**
  - ❖ Structural alerts but not CoC → **0.15 µg/person/day**
  - ❖ Carcinogens → **1.5 µg/person/day**
  - ❖ Class III chemical? → **90 µg/person/day**
  - ❖ Class II chemical? → **540 µg/person/day**
  - ❖ Class I chemical? → **1800 µg/person/day**



# THANK YOU

## TOXICOLOGY LABORATORY



# COMPLEX MATRIX

**The occurrence of an adverse health effect  
resulting from the exposure  
to group of substances  
with same or different MOA**



# SAFETY ASSESSMENT OF BOTANICALS AND BOTANICAL PREPARATIONS USE IN FOOD AS SUPPLEMENTS

- **Level A: No testing required (assumed presumption of safety)**
  - long term history of food use
  - absence of adverse effect at the proposed level of use
  - no significant increase of intake to be expected due to the intended levels of use as food supplement
  - if presence of genotoxic and carcinogenic substances, MoE approach
  - if presence of otherwise toxic substances, comparison of the overall exposure with the existing safety levels (e.g. *ADI, TMDI*) or *Margin in of Safety approach*
- **Level B: Further testing and/or data required**
  - Toxicokinetics including metabolism
  - Genotoxicity testing (*in vitro testing + in vivo testing in case of (+) results*)
  - 90 days subchronic toxicity (to establish NOAEL)
  - Other studies based on previous info (target organs, structure activity... )





# AGGREGATE AND CUMULATIVE EXPOSURE

## Aggregate Risk

The likelihood of the occurrence of an adverse health effect resulting from all routes of exposure to a single substance.

## Cumulative Risk

The likelihood of the occurrence of an adverse health effect resulting from all routes of exposure to a group of substance sharing a common mechanism of toxicity (MOA).



# **SIMPLE SIMILAR ACTION**

– Synonyms

❖ **Similar joint action**

- **All chemicals in the mixture act by the same mechanism/mode of action (MOA) and differ only in their potencies**
- **Non-interactive (i.e. the chemicals in the mixture do not influence each other's toxicity)**

## ***DOSE ADDITIVITY***



# SIMPLE DISSIMILAR ACTION

## – *Synonyms*

- ❖ Simple independent action
- ❖ Independent joint action
- **The Mode of Action (MOA) and, possibly, the nature and site of the toxic effect differ among the chemicals in the mixture**
- **Non-interactive**

## ***RESPONSE ADDITIVITY***



# TYPES OF COMBINED ACTIONS

- ➔ Simple similar action
- ➔ Simple dissimilar action
- ➔ **Interaction**
  - **Stronger than expected effect**
  - **Weaker than expected effect**



# INTERACTION

- ◆ All forms of combined action deviating from the former two types of action
- ◆ The combined effect may be
  - ◆ stronger (synergy, potentiation, supra-addition)
  - ◆ weaker (antagonism, inhibition, sub-addition)
- ◆ than that expected on the basis of dose addition



# INTERACTION

Available evidence is that  
interaction **does not occur** at  
doses that are at or below the No-  
Observable-Adverse-Effect-Level  
(NOAEL)



# INTERACTION

## ONLY DOSE ADDITIVITY SEEMS TO BE A PRIORITY IN RISK ASSESSMENT

i.e. only exposure to substances sharing a  
common MOA need to be cumulated

